Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.30 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786483 | 0.92 | ESR1 (0.34) | IKBKBAKR1C3AKR1C2LTB4RLTB4R2 | |
| SCHEMBL21786538 | 0.87 | IKBKB (0.34) | IKBKBLTB4RLTB4R2GPBAR1SCN8A | |
| SCHEMBL21786471 | 0.86 | PTGDR2 (0.39) | IKBKBLTB4RLTB4R2 | |
| SCHEMBL21786541 | 0.85 | PTGDR2 (0.36) | IKBKBLTB4RLTB4R2 | |
| SCHEMBL21786470 | 0.83 | SCN8A (0.33) | IKBKBAKR1C3AKR1C2SCN8ASCN10A | |
| SCHEMBL21786610 | 0.81 | MAPT (0.38) | — | |
| SCHEMBL21786474 | 0.80 | HTR2A (0.38) | — | |
| SCHEMBL22791108 | 0.80 | CYP11B1 (0.37) | — | |
| SCHEMBL21786481 | 0.79 | PTPN1 (0.40) | GPBAR1 | |
| SCHEMBL21786472 | 0.79 | MAPT (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | NORTHWESTERN UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | MYC, MYCBP, MYCBP2 | IKBKB 433/4885AKR1C3 3147/4885AKR1C2 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.